CINtec PLUS Triage in HPV Primary Screening

Cervical Cancer Clinical Trial

Official title:

CINtec PLUS Triage of HPV Positive Women in HPV Primary Screening

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03721484
• Other study ID #: v1.0
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 2019
• Est. completion date: December 2021

Study information

• Verified date: October 2018
• Source: Western Health and Social Care Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospective study which will recruit participants when they attend for a routine cervical screening. The study will evaluate the use of CINtec PLUS for triage of human papillomavirus (HPV) positive participants in HPV primary screening.

Description:

The study will recruit participants (9800) prospectively by verbal invitation from the sample taker when they attend for their cervical screening test. Recruitment will take up to one year to complete. Participants in the study will undergo primary HPV testing. This will be followed by cervical cytology testing as per the normal National Health Service Cervical Screening Programme (NHSCSP) screening invitation pathway. Participants testing HPV negative will have reached their end point and will exit the study. Participants who test HPV positive will be triaged by cytology (the cytology screening result, available through the NHSCSP screen will be used). Participants with moderate or severe dyskaryosis (high-grade disease) will be immediately referred to colposcopy (as per NHSCSP guidelines) without further testing. Participants with borderline or mild dyskaryosis (low-grade findings) will undergo CINtec PLUS Cytology triage simulation; however, regardless of the CINtec PLUS result, all participants will also be referred to colposcopy as per NHSCSP guidelines. Participants with negative cytology will undergo CINtec PLUS Cytology triage and those testing positive (an indication of increased risk of CIN2+ [high-grade disease]) will be referred to colposcopy. Participants with negative cytology who also test CINtec PLUS negative will only be referred to colposcopy if they have tested positive for HPV16 or HPV18 as these 2 genotypes have been shown to confer an elevated risk for CIN2+ compared with the other HPV types. Participants with negative cytology who also test CINtec PLUS negative and have tested positive for non HPV16 and HPV18 types will undergo repeat HPV testing at 12 months as the low risk of CIN2+ associated with these participants does not justify immediate colposcopy referral and is unlikely to be granted ethical approval.

Clinical outcomes based on colposcopy and/or histology and/or cervical cytology will be recorded. All biopsies will have one slide stained with CINtec Histology (p16). The risk of CIN2+ will be evaluated for all participants in the study. Subsequently, clinical performance of CINtec PLUS Cytology will be evaluated.

This work will also include a cost analysis.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 9800
• Est. completion date: December 2021
• Est. primary completion date: July 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 25 Years to 64 Years

Eligibility

Inclusion Criteria:

• Consenting women aged 25y-64y attending for cervical screening

Exclusion Criteria:

• Women aged <25y and >64y

Related Conditions & MeSH terms

• Cervical Cancer
• Uterine Cervical Neoplasms

Intervention

Diagnostic Test:
• CINtec PLUS
CINtec PLUS testing will be used to triage HPV positive women to colposcopy

Locations

Country	Name	City	State
United Kingdom	WHSCT	Londonderry	Northern Ireland

Sponsors (2)

Lead Sponsor	Collaborator
Western Health and Social Care Trust	Roche Pharma AG

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Risk of high-grade disease	CIN2+ diagnosed on biopsy obtained at colposcopy.	3 years
Primary	Risk of low-grade disease		3 years